Maxim Group Maintains Buy on Compass Pathways, Raises Price Target to $20
COMPASS Pathways Plc Sponsored ADR
COMPASS Pathways Plc Sponsored ADR CMPS | 0.00 |
Maxim Group analyst Jason McCarthy maintains Compass Pathways (NASDAQ:
CMPS) with a Buy and raises the price target from $12 to $20.
